

# ENDOLOGIX INC /DE/

## **FORM 8-K** (Current report filing)

Filed 10/03/17 for the Period Ending 10/02/17

Address	2 MUSICK IRVINE, CA, 92618
Telephone	9495957200
CIK	0001013606
Symbol	ELGX
SIC Code	3841 - Surgical and Medical Instruments and Apparatus
Industry	Medical Equipment, Supplies & Distribution
Sector	Healthcare
Fiscal Year	12/31

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 2, 2017**

---

**ENDOLOGIX, INC.**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-28440**  
(Commission  
File Number)

**68-0328265**  
(IRS Employer  
Identification No.)

**2 Musick**  
**Irvine, California**  
(Address of principal executive offices)

**92618**  
(Zip Code)

**(949) 595-7200**

**Registrant's telephone number, including area code**

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 8.01 Other Events.**

On October 2, 2017, Endologix, Inc. (the “Company”) posted information regarding its confirmatory clinical study for the Nellix EVAS System (the EVAS 2 Confirmatory IDE Study) on the [clinicaltrials.gov](http://clinicaltrials.gov) website in order to obtain a [clinicaltrials.gov](http://clinicaltrials.gov) identifier number for reimbursement purposes. The U.S. Food and Drug Administration has not yet approved the confirmatory clinical study nor has the Company initiated enrollment in such study.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 3, 2017

ENDOLOGIX, INC.

/s/ Vaseem Mahboob

---

Vaseem Mahboob  
Chief Financial Officer